Positive expression of ERβ and HER-2, larger tumor size, lymph node metastasis, postoperative chemotherapy, radiotherapy and endocrine therapy were risk prognosis factors. This evidence concerns the gene ERBB2 and metastatic malignant neoplasm in the lymph nodes.